

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

Canadian Children Inflammatory Bowel Disease Network

A PARTNERSHIP WITH THE CH.I.L.D FOUNDATION

February 2023 Newsletter

Jump to: [Education](#) | [Publications, Awards & Grants](#)

News & Reminders

- If you'll be in Halifax for the CDDW-CLM Conference, join us for a CIDSCaNN dinner on March 2, 2023. Email jennifer.debruyn@albertahealthservices.ca for details.
- CIDSCaNN logo files and revised presentation templates can be found in the [CIDSCaNN Dropbox](#), along with many other documents and resources.
- We encourage CIDSCaNN members and trainees to develop research protocols, abstracts and publications using information from the [CIDSCaNN database](#).


[Subscribe](#)[Past Issues](#)[Translate](#) ▼

progress, so please be patient if you run into glitches.

- Did you know? Conference travel funds are available for trainees and early-stage investigators who submit and present abstracts of CIDSCaNN data.



Current Projects



Phase 2 CIDSCaNN: AMBITION-CD

Assessment of Mucosal Biochemical and clinical response to Interleukin-12/23 or TNF Inhibitors in biologic-Naïve Crohn's Disease

Inclusion criteria: Children age 2-17y with Crohn's disease starting first biologic as antiTNF or UST for luminal Crohn's disease

Participating sites: All

Target: 200 antiTNF, 100 UST

Calgary and Vancouver have both enrolled their first participant in the AMBITION-CD analysis, and

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

AMBITION-CD Site Lead Meetings take place the second Tuesday of each month. The next will be on Mar 7 at 3pm (EST).

*participants
complete their 12-
month visit now!*

Biospecimen Type	Baseline (Date 0 or Anchor Date)
Biopsies	28 (41%)
DNA	37 (54%)
RNA	43 (63%)
Serum	45 (66%)
Stool	30 (44%)

Site	Enrolled in AMBITION-CD	Biologic	
		Ustekinumab	Anti TNF
Vancouver	1	0	1
Calgary	1	1	0
Ottawa	3	0	3
Toronto	30	10	20
London	10	2	8
Edmonton	12	7	5
Halifax	3	0	3
St Johns	2	1	1
Winnipeg	10	1	9
Total	72	22	50

Ongoing Follow-up of Inception Cohort Study

- Inclusion criteria: Children age 2-17y with IBD

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

Dual biologics (via Main Prevalent Cohort Study)

- Inclusion criteria: Children age 2-17y with IBD on 2 concurrent biologics
- Participating sites: All
- Enrolled: 13
- Contact: Wael welmatary@exchange.hsc.mb.ca

Predictors of response to anti-TNF therapy (Biomark study)

- Inclusion criteria: Children age 2-17y with luminal IBD starting first anti-TNF without prior surgery nor significant stenotic/penetrating disease requiring surgery in short-term
- Target: 75
- Enrolled 59
- Participating sites: Toronto, Ottawa, Halifax
- Contact: Amanda Amanda.ricciuto@sickkids.ca
- Contact: Shantel Shantel.mangroo@sickkids.ca

Implementing a Multimodal Intervention to Improve the Transition of Patients with Inflammatory Bowel Disease from Pediatric to Adult Care

- Inclusion criteria: Aged 16-17.5 y with IBD, ability to provide informed consent, ability to speak/read English at a Grade 8 level, intention to reside in Canada after transfer to adult care, access to smartphone/computer (can be purchased for the participant if this is a barrier to participation)
 - Target: 115
 - Enrolled: 28
 - Participating sites: Toronto, Ottawa, McMaster, BCCH
 - Contact: Eric eric.benchimol@sickkids.ca
-

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

Education Update

Upcoming session:

June, 2023

CIDSCaNN Educational Session 8: Managing Pediatric UC

Missed a past session? No problem! Listen to recordings at cidscann.ca/education

[Learn more & register](#)

We encourage you to share the Education Session calendar invites with your multidisciplinary teams. Please find the dates for future sessions, and past recordings at cidscann.ca/education



Publications, Awards & Grants

CIDSCaNN has submitted a **Year One Report** to the C.H.I.L.D. Foundation, detailing our progress and accomplishments in 2022. You can read a one-page summary as well as the full report on the [website](#).

Congratulations to Jocelyn Jeong, lead author of our latest CIDSCaNN publication -- [Inflammatory Bowel Disease Among Canadian Children: Comparison Between Children of Non-European Descent and Children of](#)

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

immigrant status. Our study adds to the knowledge of the impact of ancestry on IBD pathogenesis. Thank you to all those who contributed to this study!

Thank you for your engagement and contribution to CIDSCANN!

PARTICIPATING SITES



Copyright © 2022 Canadian Children Inflammatory Bowel Disease Network, All rights reserved.

Our mailing address is:

555 University Avenue, Toronto ON Canada M5G 1X8

tel: 416-813-1500

email: info@cidscann.ca

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Subscribe

Past Issues

Translate ▼

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

CIDSCaNN · 555 University Ave · Toronto, ON M5G 1X8 · Canada

Grow your business with  **mailchimp**